

MARKED-UP VERSION OF AMENDMENTS:

Specification Amendments Under 37 C.F.R. § 1.121(b)(1)(iii)

Please replace the paragraph at page 79, lines 4 through 13, with the following paragraph below, which is marked up by way of bracketing and underlining to show the changes relative to the previous version of the paragraph:

“Example 3. Functional assay for GPCR<sub>x11</sub>

GPCR<sub>x11</sub> expressing clones have been obtained by transfection of CHO-K1 cells coexpressing mitochondrial apoaequorin and Galpha16, limit dilution and selection by northern blotting. Positive clones were used for screening with a reference peptidic library containing 250 peptides and neuropeptides at a concentration of 100 nM. A specific activity was obtained with angiopeptin (D-Na[I]-Cys-Tyr-D-trp-Lys-Val-Cys-Thr-NH<sub>2</sub> (SEQ ID NO : 3[3]5) with a disulfide bridge between the two cysteines) and confirmed by a dose response curve (see Figure 15). Additional related peptides were tested using the same cells. Amongst the different peptides tested, somatostatin analog (D2-Na[I]-Cys-Tyr-D-trp-Lys-Val-Cys-D2-NaI-NH<sub>2</sub> ; SEQ ID NO : 3[4] 6) exhibited similar affinity. Somatostatin 14 has no activity on GPCR<sub>x11</sub>.”